by Alison Porter | Sep 10, 2026 | Member Spotlight
Opioid analgesics remain the primary treatment for moderate to severe pain, but often cause behavioral impairment that constrains their therapeutic utility. Preclinical antinociception assays in animals have been indispensable in the development of analgesic...
by Alison Porter | Sep 10, 2026 | Member Spotlight
Stress is an important predictor of substance use and misuse. For example, early-life or chronic stress can contribute to the development of disordered patterns of substance use. Similarly, stressful events may precipitate relapse and continued substance use among...
by Alison Porter | Apr 29, 2026 | CPDD News, News
CPDD thinklab launches with Webinar on May 13 The CPDD Education Committee is pleased to introduce the new CPDD thinklab, a Research Training & Career Development Series, with comprehensive curriculum designed to support the addiction science workforce across the...
by Alison Porter | Apr 28, 2026 | CPDD News, News
Early Career Grantee Presents their Research CPDD is pleased to spotlight the first recipients of its Early Career Investigator Grants who have completed their research and will present their findings as a poster at the 88 Annual Scientific Meeting. The Early Career...
by Alison Porter | Apr 7, 2026 | 2025 Executive Orders, CPDD News
Letter on Dosing Limits for Cannabis Dr. Ryan Vandry, a member of CPDD, has released new, science-driven recommendations to help guide federal policy on hemp-derived cannabinoid products, emphasizing a balanced approach that protects public health while preserving...
